200 related articles for article (PubMed ID: 27014261)
1. Targeting Syk in Autoimmune Rheumatic Diseases.
Deng GM; Kyttaris VC; Tsokos GC
Front Immunol; 2016; 7():78. PubMed ID: 27014261
[TBL] [Abstract][Full Text] [Related]
2. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
3. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
4. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models.
Cho S; Jang E; Yoon T; Hwang H; Youn J
Clin Exp Immunol; 2023 Mar; 211(1):31-45. PubMed ID: 36346114
[TBL] [Abstract][Full Text] [Related]
5. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.
Deng GM; Liu L; Bahjat FR; Pine PR; Tsokos GC
Arthritis Rheum; 2010 Jul; 62(7):2086-92. PubMed ID: 20222110
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases.
Zhou Y; Zhang Y; Yu W; Qin Y; He H; Dai F; Wang Y; Zhu F; Zhou G
Immun Inflamm Dis; 2023 Jul; 11(7):e934. PubMed ID: 37506139
[TBL] [Abstract][Full Text] [Related]
7. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases.
Ghosh D; Tsokos GC
Autoimmunity; 2010 Feb; 43(1):48-55. PubMed ID: 20001666
[TBL] [Abstract][Full Text] [Related]
9. Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis.
Ozaki N; Suzuki S; Ishida M; Harada Y; Tanaka K; Sato Y; Kono T; Kubo M; Kitamura D; Encinas J; Hara H; Yoshida H
Int Immunol; 2012 Sep; 24(9):539-50. PubMed ID: 22914861
[TBL] [Abstract][Full Text] [Related]
10. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
12. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
13. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
15. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Zhang Z; Cao C; Sun S; Xu Q
Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling.
Chan AC; van Oers NS; Tran A; Turka L; Law CL; Ryan JC; Clark EA; Weiss A
J Immunol; 1994 May; 152(10):4758-66. PubMed ID: 8176201
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
18. Development of a pharmacodynamic assay based on PLCĪ³2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
[TBL] [Abstract][Full Text] [Related]
19. The use of selective pharmacological inhibitors to delineate signal transduction pathways activated during complement receptor-mediated degranulation in chicken heterophils.
Kogut MH; Lowry VK; Farnell M
Int Immunopharmacol; 2003 May; 3(5):693-706. PubMed ID: 12757738
[TBL] [Abstract][Full Text] [Related]
20. The monocyte Fcgamma receptors FcgammaRI/gamma and FcgammaRIIA differ in their interaction with Syk and with Src-related tyrosine kinases.
Huang ZY; Hunter S; Kim MK; Chien P; Worth RG; Indik ZK; Schreiber AD
J Leukoc Biol; 2004 Aug; 76(2):491-9. PubMed ID: 15136586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
